A. V. Skiba
A. V. Skiba has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ivan K. Skiba
Pirogov Russian National Research Medical University
1 shared publication - Sergey E. Arakelov
Demikhov City Clinical Hospital; RUDN University
1 shared publication - Vera N. Larina
Pirogov Russian National Research Medical University
1 shared publication А. В. Скиба
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России
1 shared publicationВ. Н. Ларина
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России
1 shared publicationИ. К. Скиба
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России
1 shared publication
Latest Publications
- Open Access
- 28 October 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (4) , 367-374
Prediction of the post-hospital complications in patients with decompensated chronic heart failure
Aim . To evaluate the value of the left ventricular global function index (LVGFI) for predicting readmissions and death within 1 year after inpatient treatment for acute decompensated heart failure (ADHF). Material and methods . The study included 100 patients (51% men) aged 73.8±7.5 years hospitalised for ADHF. Follow-up lasted 12 months; the primary composite endpoint was readmission for ADHF and/or posthospital death. All patients underwent a medical history and physical examination, laboratory tests, a six-minute walk test after stabilization, and transthoracic echocardiography with subsequent calculation of the LVGFI. Results . During the follow-up period, 40 patients achieved the primary endpoint (35 patients had readmissions for ADHF alone, and 5 patients had readmissions and death due to ADHF). Based on the outcome, patients were divided into 2 groups: those with readmissions and/or death and those without adverse events. Significant differences were found between the groups in LVGFI (pConclusion . An LVGFI value of <12.6% can be considered a significant predictor of adverse outcomes (rehospitalisation and/or death) during the first year of post hospitalisation in patients who have experienced an episode of ADHF. Using LVGFI may facilitate more accurate posthospital risk stratification and identify the most vulnerable group of patients requiring more intensive monitoring and optimisation of therapy after discharge.
- 28 October 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (4) , 367-374
Open AccessPrediction of the post-hospital complications in patients with decompensated chronic heart failure
Aim . To evaluate the value of the left ventricular global function index (LVGFI) for predicting readmissions and death within 1 year after inpatient treatment for acute decompensated heart failure (ADHF). Material and methods . The study included 100 patients (51% men) aged 73.8±7.5 years hospitalised for ADHF. Follow-up lasted 12 months; the primary composite endpoint was readmission for ADHF and/or posthospital death. All patients underwent a medical history and physical examination, laboratory tests, a six-minute walk test after stabilization, and transthoracic echocardiography with subsequent calculation of the LVGFI. Results . During the follow-up period, 40 patients achieved the primary endpoint (35 patients had readmissions for ADHF alone, and 5 patients had readmissions and death due to ADHF). Based on the outcome, patients were divided into 2 groups: those with readmissions and/or death and those without adverse events. Significant differences were found between the groups in LVGFI (pConclusion . An LVGFI value of <12.6% can be considered a significant predictor of adverse outcomes (rehospitalisation and/or death) during the first year of post hospitalisation in patients who have experienced an episode of ADHF. Using LVGFI may facilitate more accurate posthospital risk stratification and identify the most vulnerable group of patients requiring more intensive monitoring and optimisation of therapy after discharge.